{"id":350184,"date":"2026-11-17T14:17:07","date_gmt":"2026-11-17T08:47:07","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=350184"},"modified":"2026-11-17T14:17:07","modified_gmt":"2026-11-17T08:47:07","slug":"cipla-vs-lupin-margins","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/cipla-vs-lupin-margins\/","title":{"rendered":"Cipla vs Lupin 2027: Same Rs 29,000 Crore Revenue, Very Different Profits and Valuations"},"content":{"rendered":"<div style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;margin:0 0 16px;\">\n<table style=\"width:100%;border-collapse:collapse;font-size:14px;\">\n<tr>\n<th style=\"text-align:left;padding:4px 10px;\">Cipla vs Lupin at a glance<\/th>\n<th style=\"text-align:left;padding:4px 10px;\">Cipla<\/th>\n<th style=\"text-align:left;padding:4px 10px;\">Lupin<\/th>\n<\/tr>\n<tr>\n<td style=\"padding:4px 10px;\"><strong>Share price (16 Nov 2026)<\/strong><\/td>\n<td style=\"padding:4px 10px;\">Rs 1,394.50<\/td>\n<td style=\"padding:4px 10px;\">Rs 1,976.70<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:4px 10px;\"><strong>Market cap<\/strong><\/td>\n<td style=\"padding:4px 10px;\">Rs 1,12,620 crore<\/td>\n<td style=\"padding:4px 10px;\">Rs 90,201 crore<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:4px 10px;\"><strong>P\/E ratio<\/strong><\/td>\n<td style=\"padding:4px 10px;\">39.47<\/td>\n<td style=\"padding:4px 10px;\">17.28<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:4px 10px;\"><strong>Q2 FY27 net profit<\/strong><\/td>\n<td style=\"padding:4px 10px;\">Rs 856.5 crore<\/td>\n<td style=\"padding:4px 10px;\">Rs 1,155 crore<\/td>\n<\/tr>\n<\/table>\n<\/div>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">Cipla vs Lupin compares two large Indian drugmakers that reported almost identical FY26 revenue of about Rs 29,040 crore but very different profits. Lupin earned Rs 5,356 crore of FY26 net profit against Rs 3,870 crore for Cipla. In Q2 FY27, both saw profits fall, with Cipla down 36.7% to Rs 857 crore and Lupin down 22.2% to Rs 1,155 crore. Lupin trades at a P\/E of 17.28, while Cipla trades at 39.47.<\/p>\n<\/div>\n<p><strong>Cipla vs Lupin<\/strong> in 2027 starts with an unusual fact: both companies reported FY26 revenue of almost exactly <strong>Rs 29,040 crore<\/strong>, yet Lupin earned about 38% more <strong>net profit<\/strong> and the market values Cipla at more than twice Lupin&#8217;s <strong>P\/E<\/strong>. The <strong>Cipla vs Lupin<\/strong> margin story explains most of that gap.<\/p>\n<p>Both are among India&#8217;s largest pharmaceutical companies, with large domestic branded businesses and big US generics operations. Cipla is a <a href=\"https:\/\/univest.in\/indices\/nifty-50\/nifty-50-share-price-today\">Nifty 50<\/a> company valued at about Rs 1,12,620 crore, and Lupin is valued at about Rs 90,201 crore. This <strong>Cipla vs Lupin<\/strong> comparison covers business models, margins, valuation, <strong>Q2 FY27 results<\/strong>, growth drivers, risks and shareholding.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=cipla-vs-lupin-margins\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/cipla-vs-lupin-margins\/#Cipla_vs_Lupin_Company_Overview\" title=\"Cipla vs Lupin: Company Overview\">Cipla vs Lupin: Company Overview<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/cipla-vs-lupin-margins\/#What_Cipla_Does\" title=\"What Cipla Does\">What Cipla Does<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/cipla-vs-lupin-margins\/#What_Lupin_Does\" title=\"What Lupin Does\">What Lupin Does<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/cipla-vs-lupin-margins\/#How_Cipla_and_Lupin_Make_Money\" title=\"How Cipla and Lupin Make Money\">How Cipla and Lupin Make Money<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/cipla-vs-lupin-margins\/#Cipla_vs_Lupin_Valuation_and_Key_Metrics\" title=\"Cipla vs Lupin Valuation and Key Metrics\">Cipla vs Lupin Valuation and Key Metrics<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/cipla-vs-lupin-margins\/#Cipla_vs_Lupin_Q2_FY27_Results_Compared\" title=\"Cipla vs Lupin Q2 FY27 Results Compared\">Cipla vs Lupin Q2 FY27 Results Compared<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/cipla-vs-lupin-margins\/#Cipla_vs_Lupin_Margins_What_Matters_in_2027\" title=\"Cipla vs Lupin Margins: What Matters in 2027\">Cipla vs Lupin Margins: What Matters in 2027<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/cipla-vs-lupin-margins\/#Cipla_rebuilding_US_margins\" title=\"Cipla: rebuilding US margins\">Cipla: rebuilding US margins<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/cipla-vs-lupin-margins\/#Lupin_holding_on_to_a_higher_base\" title=\"Lupin: holding on to a higher base\">Lupin: holding on to a higher base<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/cipla-vs-lupin-margins\/#Domestic_market_as_the_anchor\" title=\"Domestic market as the anchor\">Domestic market as the anchor<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/cipla-vs-lupin-margins\/#Risks_in_Cipla_vs_Lupin\" title=\"Risks in Cipla vs Lupin\">Risks in Cipla vs Lupin<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/cipla-vs-lupin-margins\/#Risks_for_Cipla\" title=\"Risks for Cipla\">Risks for Cipla<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/cipla-vs-lupin-margins\/#Risks_for_Lupin\" title=\"Risks for Lupin\">Risks for Lupin<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/cipla-vs-lupin-margins\/#Cipla_vs_Lupin_Shareholding\" title=\"Cipla vs Lupin Shareholding\">Cipla vs Lupin Shareholding<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/cipla-vs-lupin-margins\/#Which_Investor_Does_Each_Pharma_Stock_Suit\" title=\"Which Investor Does Each Pharma Stock Suit?\">Which Investor Does Each Pharma Stock Suit?<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/cipla-vs-lupin-margins\/#Cipla_suits_investors_who_value_franchise_strength\" title=\"Cipla suits investors who value franchise strength\">Cipla suits investors who value franchise strength<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/cipla-vs-lupin-margins\/#Lupin_suits_value-focused_pharma_investors\" title=\"Lupin suits value-focused pharma investors\">Lupin suits value-focused pharma investors<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/cipla-vs-lupin-margins\/#Final_View_on_Cipla_vs_Lupin\" title=\"Final View on Cipla vs Lupin\">Final View on Cipla vs Lupin<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/cipla-vs-lupin-margins\/#FAQs_on_Cipla_vs_Lupin\" title=\"FAQs on Cipla vs Lupin\">FAQs on Cipla vs Lupin<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/cipla-vs-lupin-margins\/#Why_did_Ciplas_profit_fall_in_Q2_FY27\" title=\"Why did Cipla&#x27;s profit fall in Q2 FY27?\">Why did Cipla&#x27;s profit fall in Q2 FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/cipla-vs-lupin-margins\/#Did_Lupins_revenue_grow_in_Q2_FY27\" title=\"Did Lupin&#x27;s revenue grow in Q2 FY27?\">Did Lupin&#x27;s revenue grow in Q2 FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/cipla-vs-lupin-margins\/#Why_is_Ciplas_PE_higher_than_Lupins\" title=\"Why is Cipla&#x27;s P\/E higher than Lupin&#x27;s?\">Why is Cipla&#x27;s P\/E higher than Lupin&#x27;s?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/cipla-vs-lupin-margins\/#Which_company_had_higher_FY26_profit\" title=\"Which company had higher FY26 profit?\">Which company had higher FY26 profit?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/cipla-vs-lupin-margins\/#What_is_the_ROE_of_Cipla_and_Lupin\" title=\"What is the ROE of Cipla and Lupin?\">What is the ROE of Cipla and Lupin?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/cipla-vs-lupin-margins\/#How_far_are_both_stocks_from_their_52-week_highs\" title=\"How far are both stocks from their 52-week highs?\">How far are both stocks from their 52-week highs?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/cipla-vs-lupin-margins\/#Is_Cipla_vs_Lupin_a_buy_or_sell_decision\" title=\"Is Cipla vs Lupin a buy or sell decision?\">Is Cipla vs Lupin a buy or sell decision?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Cipla_vs_Lupin_Company_Overview\"><\/span><strong>Cipla vs Lupin: Company Overview<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_Cipla_Does\"><\/span><strong>What Cipla Does<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Cipla is a Mumbai-based drugmaker with a strong presence in respiratory medicines, including inhalers, along with anti-infectives, cardiac and chronic therapies. It has large businesses in India, North America and South Africa.<\/p>\n<p>The company is known for its respiratory franchise in India and its complex generics pipeline for the US. Promoters hold 29.21% of the company.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_Lupin_Does\"><\/span><strong>What Lupin Does<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Lupin is a Mumbai-based pharmaceutical company with major operations in the US, India and other emerging markets. It makes generics, complex injectables, inhalation products and branded medicines in cardiac, diabetes, respiratory and central nervous system therapies.<\/p>\n<p>The promoter group holds 46.84%. Lupin&#8217;s US business recovered strongly over the last two years, which lifted its profits well above earlier levels.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_Cipla_and_Lupin_Make_Money\"><\/span><strong>How Cipla and Lupin Make Money<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Both companies earn revenue in two broad ways. In India, they sell branded generic medicines through doctors and pharmacies, where margins are steady and brand strength matters. In the US, they sell generic and specialty products, where a few complex or limited-competition launches can lift profits sharply for a few years.<\/p>\n<p>Cipla&#8217;s model leans on its respiratory franchise in India and emerging markets, plus specialty generics in the US. Lupin&#8217;s model has a larger US weight, so its profits swing more with US product launches and pricing.<\/p>\n<p>This difference shapes <strong>Cipla vs Lupin<\/strong>. When high-margin US products are contributing, profits rise fast. When those products face new competition, margins fall back.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Cipla_vs_Lupin_Valuation_and_Key_Metrics\"><\/span><strong>Cipla vs Lupin Valuation and Key Metrics<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <strong>Cipla vs Lupin<\/strong> table uses market data as of the 16 November 2026 close and trailing twelve month ratios.<\/p>\n<table style=\"width:100%;border-collapse:collapse;\" border=\"1\" cellpadding=\"8\">\n<thead>\n<tr>\n<th>Cipla vs Lupin metric<\/th>\n<th><a href=\"https:\/\/univest.in\/stocks\/cipla\/cipla-ltd-share-price-today\">Cipla<\/a><\/th>\n<th><a href=\"https:\/\/univest.in\/stocks\/lupin\/lupin-ltd-share-price-today\">Lupin<\/a><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Share price (CMP)<\/td>\n<td>Rs 1,394.50<\/td>\n<td>Rs 1,976.70<\/td>\n<\/tr>\n<tr>\n<td>52-week high<\/td>\n<td>Rs 1,539.70<\/td>\n<td>Rs 2,529.50<\/td>\n<\/tr>\n<tr>\n<td>52-week low<\/td>\n<td>Rs 1,165.70<\/td>\n<td>Rs 1,892.90<\/td>\n<\/tr>\n<tr>\n<td>Distance from 52-week high<\/td>\n<td>-9.4%<\/td>\n<td>-21.9%<\/td>\n<\/tr>\n<tr>\n<td>Market capitalisation<\/td>\n<td>Rs 1,12,620 crore<\/td>\n<td>Rs 90,201 crore<\/td>\n<\/tr>\n<tr>\n<td>P\/E ratio (TTM)<\/td>\n<td>39.47<\/td>\n<td>17.28<\/td>\n<\/tr>\n<tr>\n<td>Industry P\/E<\/td>\n<td>40.65<\/td>\n<td>40.65<\/td>\n<\/tr>\n<tr>\n<td>P\/B ratio<\/td>\n<td>3.18<\/td>\n<td>3.75<\/td>\n<\/tr>\n<tr>\n<td>Return on equity (ROE)<\/td>\n<td>8.18%<\/td>\n<td>21.65%<\/td>\n<\/tr>\n<tr>\n<td>Debt to equity<\/td>\n<td>0.02<\/td>\n<td>0.26<\/td>\n<\/tr>\n<tr>\n<td>Dividend yield<\/td>\n<td>0.93%<\/td>\n<td>0.91%<\/td>\n<\/tr>\n<tr>\n<td>FY26 revenue<\/td>\n<td>Rs 29,045 crore<\/td>\n<td>Rs 29,039 crore<\/td>\n<\/tr>\n<tr>\n<td>FY26 net profit<\/td>\n<td>Rs 3,870 crore<\/td>\n<td>Rs 5,355 crore<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The <strong>Cipla vs Lupin<\/strong> table shows Lupin trading at a <strong>P\/E of 17.28<\/strong> against 39.47 for Cipla. The pharma industry <strong>P\/E<\/strong> is 40.65, so Cipla trades close to the sector and Lupin well below it.<\/p>\n<p>Lupin has a much higher <strong>return on equity<\/strong> at 21.65% against 8.18% for Cipla. Both have low debt, with debt to equity of 0.26 for Lupin and 0.02 for Cipla. Dividend yields are similar at about 0.9%.<\/p>\n<p>FY26 is where the gap shows most clearly. Revenue was Rs 29,045 crore for Cipla and Rs 29,039 crore for Lupin, but Lupin&#8217;s <strong>net profit<\/strong> was Rs 5,356 crore against Rs 3,870 crore for Cipla.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Cipla_vs_Lupin_Q2_FY27_Results_Compared\"><\/span><strong>Cipla vs Lupin Q2 FY27 Results Compared<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Figures below are consolidated revenue and <strong>net profit<\/strong> for the quarter ended 30 September 2026.<\/p>\n<table style=\"width:100%;border-collapse:collapse;\" border=\"1\" cellpadding=\"8\">\n<thead>\n<tr>\n<th>Cipla vs Lupin Q2 FY27 (Sep 2026 quarter)<\/th>\n<th>Cipla<\/th>\n<th>Lupin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Revenue Q2 FY27<\/td>\n<td>Rs 7,555 crore<\/td>\n<td>Rs 7,954 crore<\/td>\n<\/tr>\n<tr>\n<td>Revenue Q2 FY26<\/td>\n<td>Rs 7,858 crore<\/td>\n<td>Rs 7,138 crore<\/td>\n<\/tr>\n<tr>\n<td>Revenue change YoY<\/td>\n<td>-3.9%<\/td>\n<td>+11.4%<\/td>\n<\/tr>\n<tr>\n<td>Net profit Q2 FY27<\/td>\n<td>Rs 856.5 crore<\/td>\n<td>Rs 1,155 crore<\/td>\n<\/tr>\n<tr>\n<td>Net profit Q2 FY26<\/td>\n<td>Rs 1,353 crore<\/td>\n<td>Rs 1,485 crore<\/td>\n<\/tr>\n<tr>\n<td>Net profit change YoY<\/td>\n<td>-36.7%<\/td>\n<td>-22.2%<\/td>\n<\/tr>\n<tr>\n<td>Net profit Q1 FY27<\/td>\n<td>Rs 787.1 crore<\/td>\n<td>Rs 1,417 crore<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>In the <strong>Q2 FY27 results<\/strong>, Cipla&#8217;s revenue fell 3.9% to Rs 7,555 crore and <strong>net profit<\/strong> fell 36.7% to Rs 857 crore. Its <strong>operating margin<\/strong> dropped to 20.9% from 29.1% a year earlier, though profit improved from Rs 787 crore in the June quarter.<\/p>\n<p>Lupin&#8217;s revenue rose 11.4% to Rs 7,954 crore, but net profit fell 22.2% to Rs 1,155 crore. Its <strong>operating margin<\/strong> fell to 27.9% from 35.6%, and profit was below the Rs 1,417 crore of Q1 FY27.<\/p>\n<p>For <strong>Cipla vs Lupin<\/strong>, both companies saw margins come off their peaks. Cipla&#8217;s drop was sharper, while Lupin still earns a higher margin and kept revenue growing.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Cipla_vs_Lupin_Margins_What_Matters_in_2027\"><\/span><strong>Cipla vs Lupin Margins: What Matters in 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Cipla_rebuilding_US_margins\"><\/span><strong>Cipla: rebuilding US margins<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Cipla&#8217;s <strong>operating margin<\/strong> fell about 8 points in a year, which points to pressure on the higher-margin parts of its US business. Its 2027 path depends on new complex generic and respiratory launches in the US and steady growth in India and South Africa.<\/p>\n<p>The stock trades about 9.4% below its <strong>52-week high<\/strong> of Rs 1,539.70, which suggests the market expects a recovery rather than a long decline.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Lupin_holding_on_to_a_higher_base\"><\/span><strong>Lupin: holding on to a higher base<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Lupin&#8217;s FY26 profit jumped about 62% from FY25 as its US business scaled up. The challenge for 2027 is keeping margins high as some products face more competition. Its revenue growth of 11.4% in <strong>Q2 FY27<\/strong> shows the top line is still expanding.<\/p>\n<p>In <strong>Cipla vs Lupin<\/strong>, Lupin&#8217;s low <strong>P\/E<\/strong> reflects market doubt about how long its peak margins last. Its share price of Rs 1,976.70 is close to the 52-week low of Rs 1,892.90.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Domestic_market_as_the_anchor\"><\/span><strong>Domestic market as the anchor<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Both companies have large Indian branded businesses that grow steadily regardless of US pricing. Chronic therapies such as cardiac, diabetes and respiratory are expected to keep growing faster than the overall market, which supports both companies. The <a href=\"https:\/\/univest.in\/indices\/nifty-500\/nifty-500-share-price-today\">Nifty 500<\/a> tracks the broader market both belong to.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Compare pharma stocks on the Univest Screener<\/a><\/strong><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Risks_in_Cipla_vs_Lupin\"><\/span><strong>Risks in Cipla vs Lupin<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Risks_for_Cipla\"><\/span><strong>Risks for Cipla<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Cipla&#8217;s main risk is continued margin pressure in the US, which already cut its Q2 FY27 profit by 36.7%. With a P\/E of 39.47, the stock needs a margin recovery to hold its valuation. Foreign institutions reduced their stake from 24.55% to 20.25%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Risks_for_Lupin\"><\/span><strong>Risks for Lupin<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>In the Cipla vs Lupin risk check, Lupin&#8217;s main risk is the fade of high-margin US products. Its profit has already slipped from the June quarter. US regulatory inspections of plants are a risk for both companies but matter more for Lupin&#8217;s larger US share.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Cipla_vs_Lupin_Shareholding\"><\/span><strong>Cipla vs Lupin Shareholding<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width:100%;border-collapse:collapse;\" border=\"1\" cellpadding=\"8\">\n<thead>\n<tr>\n<th>Cipla vs Lupin shareholding (Sep &#8217;26, change vs Sep &#8217;25)<\/th>\n<th>Cipla<\/th>\n<th>Lupin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Promoters<\/td>\n<td>29.21% (+0.00 pts)<\/td>\n<td>46.84% (-0.06 pts)<\/td>\n<\/tr>\n<tr>\n<td>Foreign institutions (FII)<\/td>\n<td>20.25% (-4.30 pts)<\/td>\n<td>23.28% (+2.79 pts)<\/td>\n<\/tr>\n<tr>\n<td>Domestic institutions (DII)<\/td>\n<td>34.94% (+4.69 pts)<\/td>\n<td>23.78% (-2.77 pts)<\/td>\n<\/tr>\n<tr>\n<td>Public and others<\/td>\n<td>15.61% (-0.38 pts)<\/td>\n<td>6.09% (+0.03 pts)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Cipla promoters hold 29.21%, unchanged over the year. Domestic institutions raised their stake from 30.25% to 34.94% as foreign institutions sold.<\/p>\n<p>Lupin promoters hold 46.84%. Foreign institutions raised their stake from 20.49% to 23.28%, while domestic institutions cut theirs to 23.78%. In <strong>Cipla vs Lupin<\/strong>, foreign and domestic funds moved in opposite directions in each stock.<\/p>\n<p style=\"margin-top:24px;\"><strong>Download the <a href=\"https:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"https:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Cipla and Lupin live and read daily pharma sector research.<\/strong><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Which_Investor_Does_Each_Pharma_Stock_Suit\"><\/span><strong>Which Investor Does Each Pharma Stock Suit?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Cipla_suits_investors_who_value_franchise_strength\"><\/span><strong>Cipla suits investors who value franchise strength<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Within Cipla vs Lupin, Cipla fits investors who want a respiratory-led pharma franchise with very low debt and strong domestic brands. They should accept a P\/E near 39 while margins rebuild.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Lupin_suits_value-focused_pharma_investors\"><\/span><strong>Lupin suits value-focused pharma investors<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Lupin fits investors who want higher current profitability and ROE at a P\/E below the sector. They need to accept the risk that US margins come down further.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_View_on_Cipla_vs_Lupin\"><\/span><strong>Final View on Cipla vs Lupin<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Cipla vs Lupin<\/strong> shows how two companies with the same FY26 revenue can earn very different profits. Lupin made Rs 5,356 crore and has an ROE of 21.65%, while Cipla made Rs 3,870 crore with an ROE of 8.18%, yet Cipla trades at more than twice Lupin&#8217;s P\/E.<\/p>\n<p>Both saw margins fall in Q2 FY27. The Cipla vs Lupin decision depends on whether an investor trusts Cipla&#8217;s margin recovery or Lupin&#8217;s ability to hold its higher base. US launches and domestic growth through 2027 will settle the debate.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are drawn from publicly available information and company disclosures, and they may change after publication. Please verify all data independently before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Cipla_vs_Lupin\"><\/span><strong>FAQs on Cipla vs Lupin<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Why_did_Ciplas_profit_fall_in_Q2_FY27\"><\/span><strong>Why did Cipla&#x27;s profit fall in Q2 FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Cipla&#x27;s net profit fell 36.7% to Rs 857 crore in Q2 FY27, while revenue fell 3.9% to Rs 7,555 crore. Its operating margin dropped to 20.9% from 29.1% a year earlier. This points to pressure on higher-margin US products. Profit did improve from Rs 787 crore in the June quarter.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Did_Lupins_revenue_grow_in_Q2_FY27\"><\/span><strong>Did Lupin&#x27;s revenue grow in Q2 FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Yes, Lupin&#x27;s revenue rose 11.4% to Rs 7,954 crore in Q2 FY27. Its net profit fell 22.2% to Rs 1,155 crore as the operating margin dropped to 27.9% from 35.6%. Lupin still earns a higher margin than Cipla. Profit was below the June quarter&#x27;s Rs 1,417 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_is_Ciplas_PE_higher_than_Lupins\"><\/span><strong>Why is Cipla&#x27;s P\/E higher than Lupin&#x27;s?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Cipla trades at a P\/E of 39.47 and Lupin at 17.28. The market expects Cipla&#x27;s earnings to recover from a lower base, which raises its multiple. Lupin&#x27;s lower P\/E reflects doubts about how long its high US margins can last. The pharma industry P\/E is 40.65.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_company_had_higher_FY26_profit\"><\/span><strong>Which company had higher FY26 profit?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Lupin&#x27;s FY26 net profit was Rs 5,356 crore against Rs 3,870 crore for Cipla. Both reported revenue of about Rs 29,040 crore. Lupin&#x27;s profit grew about 62% from FY25, while Cipla&#x27;s fell from Rs 5,291 crore. The difference came from margins.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_ROE_of_Cipla_and_Lupin\"><\/span><strong>What is the ROE of Cipla and Lupin?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Lupin has a return on equity of 21.65%, while Cipla&#x27;s ROE is 8.18%. Lupin earns more on its equity because of its higher profit. Both have low debt, with Cipla almost debt-free. ROE is one of several ratios used to compare drugmakers.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_far_are_both_stocks_from_their_52-week_highs\"><\/span><strong>How far are both stocks from their 52-week highs?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Cipla closed at Rs 1,394.50 on 16 November 2026, about 9.4% below its 52-week high of Rs 1,539.70. Lupin closed at Rs 1,976.70, about 21.9% below its high of Rs 2,529.50. Lupin is close to its 52-week low of Rs 1,892.90. Prices change daily.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Cipla_vs_Lupin_a_buy_or_sell_decision\"><\/span><strong>Is Cipla vs Lupin a buy or sell decision?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This Cipla vs Lupin comparison is educational and does not give a buy or sell call. Cipla offers a strong respiratory franchise at a P\/E of 39.47, and Lupin offers higher ROE at a P\/E of 17.28. Both face US margin risk. Investors should consult a SEBI-registered adviser before deciding.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"Why did Cipla's profit fall in Q2 FY27?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Cipla's net profit fell 36.7% to Rs 857 crore in Q2 FY27, while revenue fell 3.9% to Rs 7,555 crore. Its operating margin dropped to 20.9% from 29.1% a year earlier. This points to pressure on higher-margin US products. Profit did improve from Rs 787 crore in the June quarter.\"}},{\"@type\":\"Question\",\"name\":\"Did Lupin's revenue grow in Q2 FY27?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Yes, Lupin's revenue rose 11.4% to Rs 7,954 crore in Q2 FY27. Its net profit fell 22.2% to Rs 1,155 crore as the operating margin dropped to 27.9% from 35.6%. Lupin still earns a higher margin than Cipla. Profit was below the June quarter's Rs 1,417 crore.\"}},{\"@type\":\"Question\",\"name\":\"Why is Cipla's P\/E higher than Lupin's?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Cipla trades at a P\/E of 39.47 and Lupin at 17.28. The market expects Cipla's earnings to recover from a lower base, which raises its multiple. Lupin's lower P\/E reflects doubts about how long its high US margins can last. The pharma industry P\/E is 40.65.\"}},{\"@type\":\"Question\",\"name\":\"Which company had higher FY26 profit?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Lupin's FY26 net profit was Rs 5,356 crore against Rs 3,870 crore for Cipla. Both reported revenue of about Rs 29,040 crore. Lupin's profit grew about 62% from FY25, while Cipla's fell from Rs 5,291 crore. The difference came from margins.\"}},{\"@type\":\"Question\",\"name\":\"What is the ROE of Cipla and Lupin?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Lupin has a return on equity of 21.65%, while Cipla's ROE is 8.18%. Lupin earns more on its equity because of its higher profit. Both have low debt, with Cipla almost debt-free. ROE is one of several ratios used to compare drugmakers.\"}},{\"@type\":\"Question\",\"name\":\"How far are both stocks from their 52-week highs?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Cipla closed at Rs 1,394.50 on 16 November 2026, about 9.4% below its 52-week high of Rs 1,539.70. Lupin closed at Rs 1,976.70, about 21.9% below its high of Rs 2,529.50. Lupin is close to its 52-week low of Rs 1,892.90. Prices change daily.\"}},{\"@type\":\"Question\",\"name\":\"Is Cipla vs Lupin a buy or sell decision?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This Cipla vs Lupin comparison is educational and does not give a buy or sell call. Cipla offers a strong respiratory franchise at a P\/E of 39.47, and Lupin offers higher ROE at a P\/E of 17.28. Both face US margin risk. Investors should consult a SEBI-registered adviser before deciding.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Cipla vs Lupin 2027: both reported about Rs 29,040 crore of FY26 revenue, yet Lupin earned Rs 5,356 crore of profit against Rs 3,870 crore for Cipla and trades at less than half its P\/E. Here is the full comparison.<\/p>\n","protected":false},"author":34,"featured_media":350183,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[24444,3792,13958,6686,18947],"class_list":["post-350184","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-24444","tag-cipla","tag-lupin","tag-pharmaceuticals","tag-stock-comparison"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["350183"],"rank_math_title":["Cipla vs Lupin 2027: Margins, P\/E and Q2 FY27 Results"],"rank_math_description":["Cipla vs Lupin 2027: margins, Q2 FY27 results, P\/E, ROE, FY26 profit, shareholding and share price of two large Indian pharma companies compared side by side."],"rank_math_focus_keyword":["Cipla vs Lupin"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/cipla-vs-lupin-2027-same-rs-29-000-crore-revenue-very-different-profits-and.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/350184","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/34"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=350184"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/350184\/revisions"}],"predecessor-version":[{"id":350185,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/350184\/revisions\/350185"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/350183"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=350184"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=350184"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=350184"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}